TXA2 Cancer Research Results

TXA2, thromboxane A2: Click to Expand ⟱
Source:
Type:
TXA2 is a bioactive lipid mediator primarily produced via the action of cyclooxygenases (COX-1/COX-2) and thromboxane synthase (TXA2S, gene TBXAS1), and it plays a role in regulating platelet aggregation, vasoconstriction, and cellular signaling that may contribute to tumor progression.

TXA2 is a bioactive lipid mediator that, beyond its role in platelet aggregation and vascular regulation, is involved in several tumor-promoting processes such as inflammation, angiogenesis, and metastasis. In various cancers—such as breast, prostate, colorectal, lung, ovarian, and head and neck cancers—elevated TXA2 levels or enhanced signaling have been associated with more aggressive disease and poorer clinical outcomes.
CardioV, Cardiovascular Diseases: Click to Expand ⟱
Types of Cardiovascular Diseases
Coronary Artery Disease (CAD):
This is the most common type of CVD and occurs when the coronary arteries (which supply the heart with blood) are narrowed or blocked, typically due to atherosclerosis (the buildup of plaque). CAD can lead to chest pain (angina) or heart attacks.

Cerebrovascular Disease:
Diseases such as stroke fall under this category. A stroke occurs when blood flow to an area of the brain is interrupted, either by a clot (ischemic stroke) or by bleeding (hemorrhagic stroke).

Peripheral Artery Disease (PAD):
PAD involves the narrowing of peripheral arteries, often in the legs, which can cause pain and mobility issues.

Heart Failure:
Heart failure happens when the heart is unable to pump blood efficiently, leading to symptoms like shortness of breath, fatigue, and fluid retention.

Cardiac Arrhythmias:
These are problems related to the electrical system of the heart, which can cause irregular heartbeats. They range in severity from benign extra beats to life-threatening ventricular fibrillation.

Valvular Heart Diseases:
These diseases affect the heart valves, potentially causing conditions like stenosis (narrowing) or regurgitation (leakage), which can compromise the heart’s efficiency.
Scientific Papers found: Click to Expand⟱
6013- CGA,    Advances in Pharmacological Properties, Molecular Mechanisms, and Bioavailability Strategies of Chlorogenic Acid in Cardiovascular Diseases Therapy
- Review, CardioV, NA
*BioAv↝, *BioAv↝, *BP↓, *ROS↓, *NADPH↓, *AntiAg↑, *TXA2↓, *antiOx↑, *cardioP↑, *Inflam↓, *SOD↑, *Catalase↑, *Ferroptosis↓, *NF-kB↓, *JNK↓, *NRF2↑, *HO-1↑, *toxicity↓, *BioAv↓, *BioAv↑, *BioAv↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 1

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   Ferroptosis↓, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

NADPH↓, 1,  

Cell Death ⓘ

Ferroptosis↓, 1,   JNK↓, 1,  

Migration ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 2,  

Clinical Biomarkers ⓘ

BP↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   toxicity↓, 1,  
Total Targets: 20

Scientific Paper Hit Count for: TXA2, thromboxane A2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:73  Cells:%  prod#:%  Target#:1028  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page